Gennecs to inaugurate US$150M vaccine production facility, vaccine research unit in Egypt

EGYPT – Gennecs Pharmaceuticals Ltd, a research industrial-based pharmaceutical company in Egypt, is in talks with health stakeholders to develop and inaugurate a multi-vaccine production facility and a vaccine research hub valued at about US$150 million.

Gennecs portfolio is comprised of a wide range of moleculare including the production of Under Licensed Original Products, Generics, Modified Generics / Super-Generics, Vaccines, Food Supplements, as well as various Medical Devices & Laboratory Equipment.

In addition, Gennecs is an industry leader in the development and production of innovative & genetics medicines that address common medical needs as well as the Regional Distribution and Agency holder for multiple biotech products.

Egypt’s Gennecs Pharmaceuticals announced on its website that the company is in the process of establishing a vaccine manufacturing facility in Egypt and the vaccine factory will be able to produce 300 million vaccines every year.

Gennecs Pharmaceuticals offers a range of clinical, non-clinical, environmental and other development services for a wide range of applications through partnering with the state of art laboratory & facilities employing the latest technologies available in both equipment and methods.

Furthermore, the national project is expected to be the largest of its kind in the Middle East and North Africa (MENA) region and the vaccine factory will change the African market as well as position Egypt as a major player within the vaccines landscape map.

Gennecs Chief Executive Officer (CEO) Adam El Daba told Enterprise that the vaccine manufacturing facility will produce jabs included in the country’s national immunization program such as shots for HPV, polio, hepatitis A and B and other pharmaceuticals.

“The vaccine factory will begin producing ready-to-fill vials by 2026 and is expected to start producing antigens for the vaccines by 2029 after it has received accreditation from the World Health Organization (WHO),” said Adam El Daba.

CEO Adam El Daba disclosed that Gennecs Pharmaceuticals is lining up capital from foreign investors including regional and global institutions as well as family offices in Egypt, the United Arab Emirates and Saudi Arabia as well as Egypt.

Egypt’s Gennecs explores pharma prospects in manufacturing vaccines at a time when Egyptian medical authorities received the WHO’s second-highest regulatory classification which allows local firms to apply to the WHO to have their products pre-qualified and listed for emergency use.

Adam El Daba explained that the WHO prequalification is a must if you need to be accredited and start being a global pharma player, noting that the he ML-3 level of national vaccine regulation classification will allow the vaccine factory to export all over the world.

The Gennecs CEO announced that the company plans to export vaccines to all countries in the GAVI alliance, adding that the facility will have a research and development center and a “strain bank,” which catalogs different African disease strains.

He further said that the company has acquired land in an industrial zone in Greater Cairo and completed the initial design phase for the factory with help from a specialist Italian construction firm CSV Construction.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE